Clinical trials: Fat; Liver
Non Alcoholic Steatohepatitis
The Effect of Supplementation of Flaxseed, Hesperidin, Flaxseed and Hesperidin Together in Non-alcoholic Fatty Liver Disease: A Randomized, Controlled Study
To study the effects of Hesperidin, flaxseed and both together on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 100 patients who referred to…
- Trial name
- NCT03734510
- Testing
- Dietary Supplement: hesperidin and flaxseed, Dietary Supplement: hesperidin, Dietary Supplement: flaxseed
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-alcoholic Fatty Liver Disease
Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease
In China, with the improvement of living standards, there is a significant increase in the rate of prevalence of type 2 diabetes and hyperlipidemia, associated with Non-alcoholic fatty liver disease（NAFLD） which has gradually…
- Trial name
- NAFLD (NCT03648086)
- Testing
- intestinal microbiota transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongshan Hospital Xiamen University
Liver Fibrosis Due to NASH
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants…
- Trial name
- NCT01672866
- Testing
- SIM
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 222 people
- Sponsor
- Gilead Sciences
Non Alcoholic Fatty Liver Disease
Comparison of Effectiveness of Obeticholic Acid With Vitamin E in Patients of Non-alcoholic Fatty Liver Disease
This study was conducted on patients presenting to Mayo Hospital, Lahore from 24th August, 2023 till 23rd May, 2024. Ninety patients conforming to the inclusion criteria were selected via simple random sampling technique and…
- Trial name
- NCT07104786
- Testing
- Obeticholic Acid 10 MG, Vitamin E 400mg
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- King Edward Medical University
Non-alcoholic Fatty-liver Disease
Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis
Primary Objectives: 1. To determine whether a 4 week reduction in dietary fructose intake improves hepatic steatosis in overweight children who have a baseline high fructose consumption and hepatic steatosis. 2.
- Trial name
- Sweet Bev (NCT01188083)
- Testing
- Fructose Drink, Glucose Drink
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Emory University
Menopause, Non Alcholic Fatty Liver Disease
MHT and Liver Function in Postmenopausal Women
This prospective study aims to evaluate the effects of menopausal hormone therapy (MHT) on liver function, lipid profiles, and hepatic steatosis in postmenopausal women.
- Conditions
- Menopause, Non Alcholic Fatty Liver Disease, Hepatic Steatosis
- Trial name
- NCT07103603
- Testing
- Menopausal hormone therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Ipek B. Ozcivit Erkan, MD
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)
Obesity and Type 2 diabetes are creating a silent epidemic, Non-alcoholic fatty liver disease, which is a chronic liver disease associated with insulin resistance, impaired glucose intolerance, and hepatic fat accumulation.
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT00994682
- Testing
- Pioglitazone study drug, Pioglitazone Open Label
- Where
- United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of Florida
Nonalcoholic Fatty Liver
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
This study will assess the pharmacokinetics of PXL770 after 4 weeks of treatment.
- Trial name
- NCT03950882
- Testing
- PXL770
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Poxel SA
Daily Step Count, MASLD
The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With MASLD.
The study conducted a health survey among Thai adults in 2022 and found a significant increase in obesity and nonalcoholic fatty liver disease (NAFLD), leading to metabolic-associated steatotic liver disease (MASLD).
- Conditions
- Daily Step Count, MASLD, BMI, Metabolic Syndrome
- Trial name
- NCT06334666
- Testing
- Encourage using pedometer
- Where
- Thailand
- Volunteers
- 86 people
- Sponsor
- Mahidol University
NAFLD, Osteoporosis
Relation Between NAFLD and BM DENSITY
In general NAFLD is a common denominal for a broad spectrum of damage to the liver, which can be due to hepatocyte injury, inflammatory processes and fibrosis.
- Trial name
- NCT06038253
- Testing
- Fibroscan
- Volunteers
- 100 people
- Sponsor
- Assiut University
Nonalcoholic Steatohepatitis
Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)
To determine the role of pioglitazone in the treatment of nonalcoholic steatohepatitis (NASH) in patients with glucose intolerance or type 2 diabetes mellitus (T2DM).
- Trial name
- NCT00227110
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
NASH, NAFLD
Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for approximately 36% of liver-related deaths and over one…
- Trial name
- MODELS (NCT06888310)
- Testing
- extra blood sampling
- Where
- Italy
- Volunteers
- 408 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non-alcoholic Steatohepatitis (NASH)
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
- Trial name
- NCT05423327
- Testing
- No Intervention
- Where
- 50 sites in United States, Brazil and 3 more
- Volunteers
- 5,311 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Alcoholic Fatty Liver Disease
MRI and Stable Isotope Tracer Studies for Detecting the Progression of Non-Alcoholic Steatohepatitis (NASH)
One-third of the world's population suffers from Non-Alcoholic Fatty Liver Disease (NAFLD), that is a disease with an accumulation of fat in the liver.
- Trial name
- MRI-Detect (NCT04227782)
- Testing
- Magnetic Resonance Imaging, Stable Isotope Study
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Type 2 Diabetes
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Non-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, metabolic syndrome and type 2 diabetes. NAFLD, in patients with type 2 diabetes, has been shown to be associated with lipid abnormalities (such as…
- Trial name
- LIRA-NAFLD/LIP (NCT02721888)
- Testing
- Liraglutide, MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy), Blood sample
- Where
- France
- Volunteers
- 127 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Investigation on the Role of Gut-liver Axis for Non-alcoholic Steatohepatitis Through Bariatric Surgery
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Non-alcoholic steatohepatitis (NASH) is an aggressive form of NAFLD with remarkable inflammatory features which may cause advanced fibrosis and…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Bariatric Surgery
- Trial name
- NCT04501042
- Testing
- Bariatric surgery
- Where
- Taiwan
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Non-Alcoholic Fatty Liver Disease
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
- Trial name
- NCT04141592
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Queen Mary University of London
Fibrosis of Liver
Establishment of NAFLD Cohort and Development of Fibrosis Markers
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
- Trial name
- NAFLD (NCT02206841)
- Testing
- Liver biopsy, ARFI, SWE
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Boramae Hospital
Total Parenteral Nutrition-induced Cholestasis
Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants
To provide a mechanism for critically ill infants with parenteral nutrition (PN) associated cholestasis to receive Omegaven for compassionate use situations for which there are no satisfactory alternative treatments.
- Trial name
- NCT02534077
- Testing
- Omegaven
- Where
- United States
- Sponsor
- Pediatrix
Healthy Volunteers
Effect of Sucrose on Liver Fat
AIMS To determine the effect of high and low sucrose diets on liver fat in healthy adult men with liver fat levels below 5%
- Trial name
- NCT02015442
- Testing
- Sucrose
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Imperial College London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.